The new Omicron variant is not causing me to panic, but I am tweaking my portfolio a little to prepare for (likely) harder times ahead.

Ansarada is growing cash receipts, while Control Bionics is only growing expenditures…

These three companies report quarterly, but their Annual Reports still offer a valuable window into the company.

These 2 under the radar micro-caps may be high risk, high reward, but they seem to be heading in the right direction.

The Neuronode (device) and Trilogy (software), are used to help people with motor neuron disease, multiple sclerosis, cerebral palsy, and similar conditions